Updated Phase 2 Captivate Study Results Demonstrate Sustained Clinical Benefit of Fixed-Duration Imbruvica® (Ibrutinib) Plus Venetoclax as First-Line Treatment for Patients With Chronic Lymphocytic Leukaemia, Including Those With High-Risk Disease
更新的第二階段的Captivate研究結果表明，Imbruvica®（Ibrutinib）與Venetoclax一起作爲慢性淋巴細胞白血病患者的一線治療，包括高風險股票疾病患者，具有持續的臨床益處。